National Advisory Council for Human Genome Research. Statement of use of DNA testing for presymptomatic identification of
cancer risk. JAMA.1994;271:785.
American Society of Human Genetics Ad Hoc Committee on Genetic Testing
for Breast and Ovarian Cancer. Statement of genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet.1994;55:2-4.
American Society of Clinical Oncology. Genetic testing for cancer susceptibility. J Clin Oncol.1996;14:1730-1736.
Hall J, Lee M, Newman B.
et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science.1990;250:1684-1689.
Narod SA, Feunteun J, Lynch HT.
et al. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet.1991;338:82-83.
Miki Y, Swenson J, Shattuck-Eidens D.
et al. A strong candidate for the breast and ovarian cancer susceptibility
gene BRCA1. Science.1994;266:66-71.
Newman B, Moorman PG, Millikan R.
et al. The Carolina Breast Cancer Study: integrating population-based epidemiology
and molecular biology. Breast Cancer Res Treat.1995;35:51-60.
Aldrich TE, Vann D, Moorman PG, Newman B. Rapid reporting of cancer incidence in a population-based study of
breast cancer: one constructive use of a central cancer registry. Breast Cancer Res Treat.1995;35:61-64.
Weinberg CR, Wacholder S. The design and analysis of case-control studies with biased sampling. Biometrics.1990;46:963-975.
Weinberg CR, Sandler DP. Randomized recruitment in case-control studies. Am J Epidemiol.1991;134:421-432.
Friedman LS, Ostermeyer EA, Szabo CI.
et al. Confirmation of BRCA1 by analysis of germline
mutations linked to breast and ovarian cancer in ten families. Nat Genet.1994;8:399-404.
Friedman LS, Szabo CI, Ostermeyer EA.
et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi
Jewish families. Am J Hum Genet.1995;57:1284-1297.
SAS/STAT Software. Changes and Enhancements Through Release 6.11. Cary, NC: SAS Institute Inc; 1996.
Research Triangle Institute. SUDAAN Software for the Statistical Analyses of Correlated Data. Research Triangle Park, NC: Research Triangle Institute; 1996.
SAS/STAT Software. The GENMOD Procedure: SAS Technical Report p-243. Cary, NC: SAS Institute Inc; 1993.
Neuhausen SL, Mazoyer S, Friedman L.
et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet.1996;58:271-280.
Peelan T, Van Vliet M, Petrij-Bosch A.
et al. Specific mutation distribution in BRCA1 with
strong founder effects among Dutch and Belgian hereditary breast and ovarian
cancer families. Am J Hum Genet.1997;60:1041-1049.
Arena J, Smith S, Plewinska M.
et al. BRCA1 mutations in African-American women. Am J Hum Genet.1996;59:34.
Gao Q, Neuhausen S, Cummings S.
et al. Recurrent germline BRCA1 mutations in extended
African-American families with early-onset breast cancer. Am J Hum Genet.1997;60:1233-1235.
Newman B, Austin MA, Lee M, King M-C. Inheritance of human breast cancer: evidence for autosomal dominant
transmission in high-risk families. Proc Natl Acad Sci U S A.1988;85:3044-3048.
Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the Cancer and Steroid Hormone
Study. Am J Hum Genet.1991;48:232-242.
Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations
in breast cancer and ovarian cancer: results from three US population-based
case-control studies of ovarian cancer. Am J Hum Genet.1997;60:496-504.
Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and
its contribution to breast and ovarian cancer incidence. Am J Hum Genet.1995;57:1457-1462.
Schubert E, Lee M, Mefford H.
et al. BRCA2 in American families with four or more
cases of breast or ovarian cancer: recurrent and novel mutations, variable
expression, penetrance, and characteristics of families not attributable to BRCA1 or BRCA2. Am J Hum Genet.1997;60:1031-1040.
Rebbeck TR, Couch FJ, Kant J.
et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet.1996;59:547-553.
Narod S, Ford D, Devilee P.
et al. Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet.1995;57:957-958.
Easton DF, Bishop DT, Ford D.
et al. Genetic linkage analysis in familial breast and ovarian cancer: results
from 214 families. Am J Hum Genet.1993;52:678-701.
FitzGerald MG, MacDonald DJ, Krainer M.
et al. Germ-line BRCA1 mutations in Jewish and non-Jewish
women with early-onset breast cancer. N Engl J Med.1996;334:143-149.
Krainer M, Silva-Arrieta S, FitzGerald MG.
et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med.1997;336:1416-1421.
Couch FJ, DeShano ML, Blackwood A.
et al. BRCA1 mutations in women attending clinics
that evaluate the risk of breast cancer. N Engl J Med.1997;336:1409-1415.
Shattuck-Eidens D, Oliphant A, McClure M.
et al. BRCA1 sequence analysis in women at high risk
for susceptibility mutations: risk factor analysis and implications for genetic
Langston AA, Malone KE, Thompson JD.
et al. BRCA1 mutations in a population-based sample
of young women with breast cancer. N Engl J Med.1996;334:137-142.
Durocher F, Shattuck-Eidens D, McClure M.
et al. Comparison of BRCA1 polymorphisms, rare sequence
variants and/or missense mutations in unaffected and breast/ovarian cancer
populations. Hum Mol Genet.1996;5:835-842.
Sachs AB. Messenger RNA degradation in eukaryotes. Cell.1993;74:413-421.
Struewing JP, Hartge P, Wacholder S.
et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med.1997;336:1401-1408.
Langston AA, Stanford JL, Wicklund KG.
et al. Germ-line BRCA1 mutations in selected men
with prostate cancer. Am J Hum Genet.1996;58:881-885.
Ford D, Easton DF, Bishop DT.
et al. Risks of cancer in BRCA1-mutation carriers. Lancet.1994;343:692-695.
Margaritte P, Bonaiti-Pellie C, King M-C, Clerget-Darpoux F. Linkage of familial breast cancer to chromosome 17q21 may not be restricted
to early-onset disease. Am J Hum Genet.1992;50:1231-1234.
Puget N, Torchard D, Serova-Sinilnikova OM.
et al. A 1-kb Alu-mediated germline deletion removing BRCA1 exon 17. Cancer Res.1997;57:828-831.
Petrij-Bosch A, Peelen T, van Vliet M.
et al. BRCA1 genomic deletions are major founder
mutations in Dutch breast cancer patients. Nat Genet.1997;17:341-345.
Serova O, Mazoyer S, Puget N.
et al. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer susceptibility
genes? Am J Hum Genet.1997;60:486-495.
Kerlikowske K, Grady D, Rubin S.
et al. Efficacy of screening mammography: a meta-analysis. JAMA.1995;273:149-154.
Fletcher SW. Whither scientific deliberation in health policy recommendations? Alice
in the Wonderland of breast-cancer screening. N Engl J Med.1997;336:1180-1183.
Kerlikowske K, Grady D, Barclay J.
et al. Effect of age, breast density, and family history on the sensitivity
of first screening mammography. JAMA.1996;276:33-38.
Hartmann L, Jenkins R, Schaid D, Yang P. Prophylactic mastectomy: preliminary retrospective cohort analysis
[abstract]. Proc Am Assoc Cancer Res.1997;38:168.
Ford LG, Johnson KA. Tamoxifen breast cancer prevention trial—an update. Prog Clin Biol Res.1997;396:271-282.
Collins FS. BRCA1 —lots of mutations, lots of dilemmas. N Engl J Med.1996;334:186-188.
Healy B. BRCA genes—bookmaking, fortunetelling,
and medical care. N Engl J Med.1997;336:1448-1449.
Rothenberg K, Fuller B, Rothstein M.
et al. Genetic information and the workplace: legislative approaches and policy
Rothenberg KH. Genetic information and health insurance: state legislative approaches. J Law Med Ethics.1995;23:312-319.
Hubbard R, Lewontin RC. Pitfalls of genetic testing. N Engl J Med.1996;334:1192-1194.
Hubbard R, Wald E. Exploding the Gene Myth. Boston, Mass: Beacon Press; 1993.
Bradley MB, Green Jr NM, Jones DE.
et al. Churches and Church Membership in the United States, 1990. Atlanta, Ga: Glenmary Research Center; 1992.